Forty-seven accounts on Hyperliquid increased or opened new long positions in HIP-3 contracts linked to U.S. technology stocks, totaling $39 million in new exposure. Each asset saw new long exposure exceeding $500,000, reflecting investor confidence despite pressure on tech shares. This activity includes both new positions and additions to existing ones, indicating a strategic bet on tech stock recovery or growth. The move highlights ongoing investor interest in U.S. tech amid market fluctuations.
The story about 47 Hyperliquid accounts adding $39 million to U.S. stock-linked longs provides context for market activity. For readers following cryptocurrency trends, here is Pluang's market snapshot as of Oct 24, 2026 02:31 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell. Notable movers include BCH at Rp5.144.657 (+4.45%), SAND at Rp938 (-4.41%), and COTI at Rp202 (+3.90%).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
